Burden of Disease in Real-Life Setting of Patients With Atopic Dermatitis: Italian Data From the MEASURE-AD Study

Giuseppe  Argenziano; Santo Raffaele  Mercuri; Paola  Savoia; Paolo  Amerio; Anna Belloni  Fortina; Maria Rita Bongiorno; Maria Beatrice  De Felici Del Giudice; Aurora Parodi; Nicola Pimpinelli; Luca Stingeni; Michela  Ortoncelli; Giuseppe Stinco; Giuliana Gualberti; Anna Levi; Valeria Scuderi; Luca  Bianchi; Giovanna  Malara

doi:10.5826/dpc.1401a79

Authors

Giuseppe Argenziano Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples
Santo Raffaele Mercuri Unit of Dermatology, IRCCS San Raffaele Hospital, Milan
Paola Savoia Department of Health Sciences, Università del Piemonte Orientale, Novara
Paolo Amerio Dermatologic Clinic, Department of Medicine and Aging Science and Dermatologic Clinic, University "G. d'Annunzio", Chieti-Pescara, Chieti
Anna Belloni Fortina Unit of Pediatric Dermatology, Department of Medicine DIMED, University of Padua, Padua
Maria Rita Bongiorno Section of Dermatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo
Maria Beatrice De Felici Del Giudice Dermatologic Unit, University Hospital of Parma, Department of medicine and surgery, Parma
Aurora Parodi Division of Dermatology, Department of Health Sciences (DISSAL), University of Genoa, Genoa Italy and Ospedale Policlinico San Martino IRCCS, Genoa
Nicola Pimpinelli Dermatology Unit, Dept. Health Sciences, University of Florence, Florence
Luca Stingeni Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia
Michela Ortoncelli Medical Sciences Department, Dermatologic Clinic, University of Turin, Turin
Giuseppe Stinco Institute of Dermatology, University of Udine, Udine
Giuliana Gualberti a:1:{s:5:"en_US";s:10:"Abbvie SRL";}
Anna Levi AbbVie SrL, Campoverde di LT
Valeria Scuderi AbbVie SrL, Campoverde di LT
Luca Bianchi Dermatology Unit, Tor Vergata University Hospital, Rome
Giovanna Malara UOC of Dermatology, Grande Ospedale Metropolitano "Bianchi Melacrino Morelli", Reggio Calabria

Keywords:

real-life, moderate-to-severe atopic dermatitis, burden, patient-reported outcomes, QoL

Abstract

Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease that negatively impacts the quality of life and work productivity of patients.

Objectives: We sought to evaluate the real-world burden of AD patients in Italy.

Methods: This sub-analysis of the MEASURE-AD multicountry study conducted between December 2019-2020 included patients diagnosed with moderate-to-severe AD eligible for receiving systemic therapy in the previous 6 months. During a single visit, physician and patient-reported questionnaires were used.

Results: A total of 118 adult patients were enrolled and 57.6% (N = 68) of patients had moderate-to-severe AD at the time of enrolment according to the Eczema Area and Severity Index.Sleep disorders interfered with daily function in the previous week in 58.5% (N = 69) of patients, pru-ritus was severe in 50% (N = 59) and 42.4% (N = 50) reported a flare lasting >7 days in the previous 6 months.According to the Dermatology Quality of Life Index, 37.3% (N = 44) of patients reported a severe impact of AD and approximately 10% had clinical depression/anxiety. Current drug therapy was considered inadequate in controlling AD in 26.3% (N=31) of patients.Work activity impairment was 38.6±31.7% and monthly AD-related expenses were 148.6±134.6 Euros per patient.

Conclusions: This real-life study documents a high burden of disease in patients with moderate-severe AD in Italy.

References

Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77(2):274-279.e3. doi:10.1016/j.jaad.2017.04.019

Silverberg JI, Chiesa Fuxench ZC, Gelfand JM, et al. Content and construct validity, predictors, and distribution of self-reported atopic dermatitis severity in US adults. Ann Allergy Asthma Immunol. 2018;121(6):729-734.e4. doi:10.1016/j.anai.2018.07.040

Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409-1431. doi:10.1111/jdv.18345

Mostafa N, Phan K, Lai B, Smith SD. Comparing quality of life outcomes of JAK inhibitors and biological treatments for atopic dermatitis: a systematic review and network meta-analysis. Expert Rev Clin Pharmacol. 2021;14(11):1435-1444. doi:10.1080/17512433.2021.1970529

Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. JAMA Dermatology. 2022;158(4):404-413. doi:10.1001/jamadermatol.2022.0029

Patrizi A, Costanzo A, Patruno C, Busà VM, Chiricozzi A, Girolomoni G. Unmet needs in atopic dermatitis management: an expert consensus. J Dermatolog Treat. 2022;33(5):2459-2465. doi:10.1080/09546634.2021.1967267

Drucker AM, Wang AR, Qureshi AA. Research Gaps in Quality of Life and Economic Burden of Atopic Dermatitis: The National Eczema Association Burden of Disease Audit. JAMA Dermatol. 2016;152(8):873-874. doi:10.1001/jamadermatol.2016.1978

Kim JP, Chao LX, Simpson EL, Silverberg JI. Persistence of atopic dermatitis (AD): A systematic review and meta-analysis. J Am Acad Dermatol. 2016;75(4):681-687.e11. doi:10.1016/j.jaad.2016.05.028

Lobefaro F, Gualdi G, Di Nuzzo S, Amerio P. Atopic Dermatitis: Clinical Aspects and Unmet Needs. Biomedicines. 2022;10(11):2927. doi:10.3390/biomedicines10112927

Gisondi P. The multidimensional burden of psoriasis. British Journal of Dermatology. 2018;179(1):13-14. doi:10.1111/bjd.16686

Kleyn CE, Barbarot S, Reed C, et al. Burden of Moderate to Severe Atopic Dermatitis in Adults from France, Italy, and the UK: Patient-Reported Outcomes and Treatment Patterns. Dermatol Ther (Heidelb). 2022;12(8):1947-1965. doi:10.1007/s13555-022-00777-z

Elsawi R, Dainty K, Smith Begolka W, et al. The Multidimensional Burden of Atopic Dermatitis Among Adults: Results From a Large National Survey. JAMA Dermatol. 2022;158(8):887-892. doi:10.1001/jamadermatol.2022.1906

de Bruin-Weller M, Gadkari A, Auziere S, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2020;34(5):1026-1036. doi:10.1111/jdv.16003

WAO. World Allergy Organization (WAO) White Book on Allergy: Update 2013. https://www.worldallergy.org/UserFiles/file/WhiteBook2-2013-v8.pdf

Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491-498. doi:10.1016/j.jaad.2015.10.043

Whiteley J, Emir B, Seitzman R, Makinson G. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1645-1651. doi:10.1080/03007995.2016.1195733

Miniotti M, Lazzarin G, Ortoncelli M, Mastorino L, Ribero S, Leombruni P. Impact on health-related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate-to-severe atopic dermatitis. Dermatol Ther. 2022;35(5):e15407. doi:10.1111/dth.15407

Ribero S, Giura MT, Viola R, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real-life Italian tertiary centre experience. J Eur Acad Dermatol Venereol. 2020;34(8):e380-e383. doi:10.1111/jdv.16219

Chiricozzi A, Gori N, Di Nardo L, et al. Therapeutic Impact and Management of Persistent Head and Neck Atopic Dermatitis in Dupilumab-Treated Patients. Dermatology. 2022;238(4):717-724. doi:10.1159/000519361

Mastorino L, Rosset F, Gelato F, et al. Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients. Pharmaceuticals (Basel). 2022;15(7):883. doi:10.3390/ph15070883

Milanesi N, Gola M, Cartocci A, et al. Effect of dupilumab on sleep disturbances in adult patients with severe atopic dermatitis. Ital J Dermatol Venerol. 2022;157(2):142-145. doi:10.23736/S2784-8671.21.07072-9

Gori N, Chiricozzi A, Marsili F, et al. National Information Campaign Revealed Disease Characteristic and Burden in Adult Patients Suffering from Atopic Dermatitis. J Clin Med. 2022;11(17):5204. doi:10.3390/jcm11175204

Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10(1):11-18. doi:10.1034/j.1600-0625.2001.100102.x

Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353-1357. doi:10.1111/bjd.13662

Chopra R, Vakharia PP, Sacotte R, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177(5):1316-1321. doi:10.1111/bjd.15641

Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169(6):1326-1332. doi:10.1111/bjd.12590

Vakharia PP, Chopra R, Sacotte R, et al. Severity strata for five patient-reported outcomes in adults with atopic dermatitis. Br J Dermatol. 2018;178(4):925-930. doi:10.1111/bjd.16078

Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010;162(3):587-593. doi:10.1111/j.1365-2133.2009.09586.x

Foley C, Tundia N, Simpson E, Teixeira HD, Litcher-Kelly L, Bodhani A. Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: the Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS). Curr Med Res Opin. 2019;35(7):1139-1148. doi:10.1080/03007995.2018.1560222

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216.

Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370. doi:10.1111/j.1600-0447.1983.tb09716.x

Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353-365. doi:10.2165/00019053-199304050-00006

Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology (Oxford). 2010;49(4):812-819. doi:10.1093/rheumatology/kep457

Simpson EL, Guttman-Yassky E, Margolis DJ, et al. Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis. JAMA Dermatol. 2018;154(8):903-912. doi:10.1001/jamadermatol.2018.1572

Ferrucci SM, Tavecchio S, Angileri L, Surace T, Berti E, Buoli M. Factors Associated with Affective Symptoms and Quality of Life in Patients with Atopic Dermatitis. Acta Derm Venereol. 2021;101(11):adv00590. doi:10.2340/00015555-3922

Offidani A, Stingeni L, Neri I, et al. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24. Ital J Dermatol Venerol. 2022;157(1):39-46. doi:10.23736/S2784-8671.21.06952-2

Buoli M, Grassi S, Serati M, Altamura AC. Agomelatine for the treatment of generalized anxiety disorder. Expert Opin Pharmacother. 2017;18(13):1373-1379. doi:10.1080/14656566.2017.1359257

Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi:10.1038/s41572-018-0001-z

Andersen L, Nyeland ME, Nyberg F. Increasing severity of atopic dermatitis is associated with a negative impact on work productivity among adults with atopic dermatitis in France, Germany, the U.K. and the U.S.A. Br J Dermatol. 2020;182(4):1007-1016. doi:10.1111/bjd.18296

Holm EA, Esmann S, Jemec GBE. The handicap caused by atopic dermatitis--sick leave and job avoidance. J Eur Acad Dermatol Venereol. 2006;20(3):255-259. doi:10.1111/j.1468-3083.2006.01416.x

Stingeni L, Belloni Fortina A, Baiardini I, Hansel K, Moretti D, Cipriani F. Atopic Dermatitis and Patient Perspectives: Insights of Bullying at School and Career Discrimination at Work. J Asthma Allergy. 2021;14:919-928. doi:10.2147/JAA.S317009

Augustin M, Misery L, von Kobyletzki L, Armario-Hita J c., Mealing S, Redding M. Unveiling the true costs and societal impacts of moderate-to-severe atopic dermatitis in Europe. Journal of the European Academy of Dermatology and Venereology. 2022;36(S7):3-16. doi:10.1111/jdv.18168

Sciattella P, Pellacani G, Pigatto PD, et al. The burden of atopic dermatitis in adults in Italy. G Ital Dermatol Venereol. 2020;155(1):19-23. doi:10.23736/S0392-0488.19.06430-7

Augustin M, Costanzo A, Pink A, et al. Real-World Treatment Patterns and Treatment Benefits among Adult Patients with Atopic Dermatitis: Results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey. Acta Derm Venereol. 2022;102:adv00830. doi:10.2340/actadv.v102.3932

Ferrucci SM, Tavecchio S, Marzano AV, Buffon S. Emerging Systemic Treatments for Atopic Dermatitis. Dermatol Ther (Heidelb). 2023;13(5):1071-1081. doi:10.1007/s13555-023-00920-4

Silverberg J i., Thyssen J p., Fahrbach K, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. Journal of the European Academy of Dermatology and Venereology. 2021;35(9):1797-1810. doi:10.1111/jdv.17351

Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatology. 2021;157(9):1047-1055. doi:10.1001/jamadermatol.2021.3023